| NCT06525220 | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | RECRUITING | PHASE3 | 2024-09-25 | 2030-07 | 2028-01 |
| NCT06496178 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | RECRUITING | PHASE3 | 2024-06-25 | 2029-03 | 2028-02 |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | TERMINATED | PHASE2 | 2022-11-17 | 2025-07-03 | 2025-07-03 |
| NCT04868877 | Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | RECRUITING | PHASE1, PHASE2 | 2021-04-28 | 2027-03 | 2026-03 |
| NCT03922204 | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies | COMPLETED | PHASE1 | 2019-05-08 | 2024-11-07 | 2024-11-07 |
| NCT03526835 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2018-05-02 | 2027-11 | 2025-11 |
| NCT03321981 | MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer. | COMPLETED | PHASE2 | 2018-01-15 | 2023-07-26 | 2022-10-26 |
| NCT03038230 | MCLA-117 in Acute Myelogenous Leukemia | TERMINATED | PHASE1 | 2016-04 | 2021-05-11 | 2021-05-11 |